...
search icon
cntb-img

Connect Biopharma Holdings Ltd, Common Stock

CNTB

NMQ

$0.9224

-$0.05

(-5.15%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$50.97M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
7.20K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.31
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.91 L
$2.66 H
$0.9224

About Connect Biopharma Holdings Ltd, Common Stock

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCNTBSectorS&P500
1-Week Return-6.41%-0.03%1.53%
1-Month Return-12.98%4.56%4.75%
3-Month Return-6.83%1.29%2.77%
6-Month Return-21.16%-3.54%12.18%
1-Year Return-23.13%1.59%22.34%
3-Year Return-79.18%13.55%38.91%
5-Year Return-95.01%40.85%80.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue---1.03M988.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.86,"profit":true}]
Gross Profit---(1.03M)(988.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-103063400,"profit":false},{"date":"2023-12-31","value":-98800000,"profit":false}]
Gross Margin---(Infinity%)(Infinity%)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses113.29M29.36M97.59M114.69M62.07M[{"date":"2019-12-31","value":98.78,"profit":true},{"date":"2020-12-31","value":25.6,"profit":true},{"date":"2021-12-31","value":85.09,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":54.13,"profit":true}]
Operating Income(110.24M)(30.30M)(99.15M)(117.66M)(62.07M)[{"date":"2019-12-31","value":-11024100000,"profit":false},{"date":"2020-12-31","value":-3029531300,"profit":false},{"date":"2021-12-31","value":-9915186900,"profit":false},{"date":"2022-12-31","value":-11766164400,"profit":false},{"date":"2023-12-31","value":-6207400000,"profit":false}]
Total Non-Operating Income/Expense(57.37M)(91.25M)(102.64M)10.17M5.38M[{"date":"2019-12-31","value":-564.27,"profit":false},{"date":"2020-12-31","value":-897.48,"profit":false},{"date":"2021-12-31","value":-1009.46,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.93,"profit":true}]
Pre-Tax Income(168.63M)(119.37M)(204.94M)(116.12M)(59.38M)[{"date":"2019-12-31","value":-16862500000,"profit":false},{"date":"2020-12-31","value":-11936947700,"profit":false},{"date":"2021-12-31","value":-20493887200,"profit":false},{"date":"2022-12-31","value":-11611767900,"profit":false},{"date":"2023-12-31","value":-5938300000,"profit":false}]
Income Taxes(3.05M)934.46K266.47K297.52K120.00K[{"date":"2019-12-31","value":-326.39,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":28.52,"profit":true},{"date":"2022-12-31","value":31.84,"profit":true},{"date":"2023-12-31","value":12.84,"profit":true}]
Income After Taxes(165.57M)(120.30M)(205.21M)(116.42M)(59.50M)[{"date":"2019-12-31","value":-16557500000,"profit":false},{"date":"2020-12-31","value":-12030393600,"profit":false},{"date":"2021-12-31","value":-20520534500,"profit":false},{"date":"2022-12-31","value":-11641519600,"profit":false},{"date":"2023-12-31","value":-5950300000,"profit":false}]
Income From Continuous Operations(168.63M)(779.23M)(1.31B)(797.05M)(59.50M)[{"date":"2019-12-31","value":-16862500000,"profit":false},{"date":"2020-12-31","value":-77922500000,"profit":false},{"date":"2021-12-31","value":-130682400000,"profit":false},{"date":"2022-12-31","value":-79705500000,"profit":false},{"date":"2023-12-31","value":-5950300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(165.57M)(120.30M)(205.21M)(116.42M)(59.50M)[{"date":"2019-12-31","value":-16557500000,"profit":false},{"date":"2020-12-31","value":-12030393600,"profit":false},{"date":"2021-12-31","value":-20520534500,"profit":false},{"date":"2022-12-31","value":-11641519600,"profit":false},{"date":"2023-12-31","value":-5950300000,"profit":false}]
EPS (Diluted)-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CNTB
Cash Ratio 11.45
Current Ratio 12.04
Quick Ratio 12.07

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CNTB
ROA (LTM) -12.13%
ROE (LTM) -17.92%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CNTB
Debt Ratio Lower is generally better. Negative is bad. 0.08
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.92

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CNTB
Trailing PE NM
Forward PE 0.77
P/S (TTM) 2.11
P/B 0.46
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.19

FAQs

What is Connect Biopharma Holdings Ltd share price today?

Connect Biopharma Holdings Ltd (CNTB) share price today is $0.9224

Can Indians buy Connect Biopharma Holdings Ltd shares?

Yes, Indians can buy shares of Connect Biopharma Holdings Ltd (CNTB) on Vested. To buy Connect Biopharma Holdings Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CNTB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Connect Biopharma Holdings Ltd be purchased?

Yes, you can purchase fractional shares of Connect Biopharma Holdings Ltd (CNTB) via the Vested app. You can start investing in Connect Biopharma Holdings Ltd (CNTB) with a minimum investment of $1.

How to invest in Connect Biopharma Holdings Ltd shares from India?

You can invest in shares of Connect Biopharma Holdings Ltd (CNTB) via Vested in three simple steps:

  • Click on Sign Up or Invest in CNTB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Connect Biopharma Holdings Ltd shares
What is Connect Biopharma Holdings Ltd 52-week high and low stock price?

The 52-week high price of Connect Biopharma Holdings Ltd (CNTB) is $2.66. The 52-week low price of Connect Biopharma Holdings Ltd (CNTB) is $0.91.

What is Connect Biopharma Holdings Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Connect Biopharma Holdings Ltd (CNTB) is 0.46

What is the Market Cap of Connect Biopharma Holdings Ltd?

The market capitalization of Connect Biopharma Holdings Ltd (CNTB) is $50.97M

What is Connect Biopharma Holdings Ltd’s stock symbol?

The stock symbol (or ticker) of Connect Biopharma Holdings Ltd is CNTB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top